Inclusion body myositis, viral infections, and TDP-43: a narrative review.
Vitalie VăcăraşRomana VulturarAdina ChişLaura-Otilia DamianPublished in: Clinical and experimental medicine (2024)
The ubiquitous RNA-processing molecule TDP-43 is involved in neuromuscular diseases such as inclusion body myositis, a late-onset acquired inflammatory myopathy. TDP-43 solubility and function are disrupted in certain viral infections. Certain viruses, high viremia, co-infections, reactivation of latent viruses, and post-acute expansion of cytotoxic T cells may all contribute to inclusion body myositis, mainly in an age-shaped immune landscape. The virally induced senescent, interferon gamma-producing cytotoxic CD8+ T cells with increased inflammatory, and cytotoxic features are involved in the occurrence of inclusion body myositis in most such cases, in a genetically predisposed host. We discuss the putative mechanisms linking inclusion body myositis, TDP-43, and viral infections untangling the links between viruses, interferon, and neuromuscular degeneration could shed a light on the pathogenesis of the inclusion body myositis and other TDP-43-related neuromuscular diseases, with possible therapeutic implications.
Keyphrases
- late onset
- interstitial lung disease
- myasthenia gravis
- amyotrophic lateral sclerosis
- sars cov
- systemic sclerosis
- early onset
- risk assessment
- dendritic cells
- rheumatoid arthritis
- drug induced
- endothelial cells
- acute respiratory distress syndrome
- high glucose
- extracorporeal membrane oxygenation
- idiopathic pulmonary fibrosis